In this week's rheumatology news roundup, we feature a Q&A with Dr. Aryeh M. Abeles who talks with Rheumatology Network about his concerns with the black box warning label for the gout treatment febuxostat. We also include a story on addressing prescription abdandonment in rheumatoloyg. These and other stories in today's news roundup.
Rheumatology Network Editorial Staff
This week, the British medical journal The Lancet, launched a new journal that focuses strictly on rheumatology. Aptly called "The Lancet Rheumatology," the journal's mission is to "provide an independent voice to the rheumatology community and to the millions of patients living with these conditions."
Can gluten-containing food products trigger a psoriatic arthritis flare? How well does the average psoriatic arthritis patient understand their condition? Learn more in today's psoriatic arthritis quiz.
In this slideshow, we revisit some of our most popular stories on spondyloarthritis published in recent weeks. From making an accurate diagnosis to assessing a confusing case of back pain, learn more in this slideshow.
AbbVie announced on Friday that the Food and Drug Administration approved the oral once-daily JAK inhibitor Rinvoq (upadacitinib) for adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
In today's news roundup from Rheumatology Network, we highlight recent findings from ACR Open Rheumatology that examine infection risk in rheumatoid arthritis patients. Plus, we conduct a Q&A from a presentation made at the Rheumatology Nurses Society on alternative treatments for rheumatology conditions.
Axial psoriatic arthritis is sometimes confused with ankylosing spondylitis. What are the features that distinguish these conditions from each other? In this quiz, test your knowledge about this and other features of PsA.
The jury is still out on whether vitamin D supplementation can prevent and improve knee osteoarthritis, according to a review published in ACR Open Rheumatology.
Adults with rapid onset knee osteoarthritis that occurs and progressess within as little as four years, are more likely to receive pharmacological treatments or even surgery than those who live with the condition long-term.
The JAK1 inhibitor filgotinib has been shown to be effective in rheumatoid arthritis patients who failed previous treatment with one or more biologic DMARD.